Mecasermin

1. Mecasermin extends lifespan in mice.

   “treatment with recombinant IGF-1 delays the onset of many progeroid features in these animals and significantly extends their lifespan.”

   Reviewin Zmpste24-/- mice

   Rejuvenating somatotropic signaling: a therapeutical opportunity for premature aging?

   Aging·1 Dec 2010

2. Mecasermin extends lifespan in mice.

   “recombinant IGF-1 treatment restores the proper balance between IGF-1 and GH in Zmpste24(-/-) mice, delays the onset of many progeroid features, and significantly extends the lifespan of these progeroid animals.”

   Animalsin progeroid Zmpste24(-/-) mice

   Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function

   Proceedings of the National Academy of Sciences of the United States of America·30 Aug 2010

1. Mecasermin decreases progeroid features in mice.

   “treatment with recombinant IGF-1 delays the onset of many progeroid features in these animals”

   Reviewin Zmpste24-/- mice

   Rejuvenating somatotropic signaling: a therapeutical opportunity for premature aging?

   Aging·1 Dec 2010

1. Mecasermin improves somatotroph axis function in mice.

   “recombinant IGF-1 treatment restores the proper balance between IGF-1 and GH in Zmpste24(-/-) mice”

   Animalsin Zmpste24(-/-) mice

   Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function

   Proceedings of the National Academy of Sciences of the United States of America·30 Aug 2010

1. Mecasermin protects against progeria in mice.

   “delays the onset of many progeroid features”

   Animalsin Zmpste24(-/-) mice

   Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function

   Proceedings of the National Academy of Sciences of the United States of America·30 Aug 2010

More on Progeria

1. Mecasermin increases IGFBP-2 in rats (136-235%).

   “a larger increase in the 30-34 kDa IGFBP (BP-2; 136-235%) following IGF-I treatment in the older (16-24 months) animals.”

   Animalsinfusion1.2 mg/kg/day2 weeksmales

   The differential regulation of insulin-like growth factor (IGF) binding proteins by IGF-I during the life span of the rat

   Journal of gerontology·1 Sep 1994

More on IGFBP-2

1. Mecasermin increases alkaline phosphatase in rats (26%).

   “serum phosphorous (20%), and alkaline phosphatase (26%) compared to age-matched controls.”

   Animalsinfusion1.2 mg/kg/day2 weeksmales

   The differential regulation of insulin-like growth factor (IGF) binding proteins by IGF-I during the life span of the rat

   Journal of gerontology·1 Sep 1994

More on Alkaline phosphatase

1. Mecasermin increases phosphorus in rats (20%).

   “Anabolic actions of IGF-I, which were seen only in the older rats, included modes increases in weight velocity (5.2 +/- 1.2 g/week), serum phosphorous (20%)”

   Animalsinfusion1.2 mg/kg/day2 weeksmales

   The differential regulation of insulin-like growth factor (IGF) binding proteins by IGF-I during the life span of the rat

   Journal of gerontology·1 Sep 1994

More on Phosphorus

1. Mecasermin increases weight velocity in rats (5.2 +/- 1.2 g/week).

   “Anabolic actions of IGF-I, which were seen only in the older rats, included modes increases in weight velocity (5.2 +/- 1.2 g/week)”

   Animalsinfusion1.2 mg/kg/day2 weeksmales

   The differential regulation of insulin-like growth factor (IGF) binding proteins by IGF-I during the life span of the rat

   Journal of gerontology·1 Sep 1994

1. Mecasermin is associated with IGF1R in silico.

   “Eventually, mecasermin could stably bind to IGF1R”

   In silicocomputational binding analysis

   Identification and analysis of immune aging related biomarkers in cartilage and meniscus tissues of osteoarthritis

   American journal of clinical and experimental immunology·15 Aug 2025

More on IGF1R